Indivior Pharmaceuticals, Inc. (INDV)

34.77 +0.90 (+2.66%) USD  |  NASDAQ  |  Oct 20, 16:00
35.09 +0.32 (+0.92%) Pre-Market: 08:02
More

Indivior Pharmaceuticals Research and Development Expense (TTM) : 53.00M for June 30, 2026

Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 53.00M
March 31, 2026 67.00M
December 31, 2025 80.00M
September 30, 2025 94.00M
June 30, 2025 96.00M
March 31, 2025 101.00M
December 31, 2024 107.00M
September 30, 2024 106.00M
June 30, 2024 102.00M
March 31, 2024 108.00M
December 31, 2023 107.00M
September 30, 2023 106.00M
June 30, 2023 108.00M
March 31, 2023 90.00M
December 31, 2022 71.00M
September 30, 2022 61.00M
June 30, 2022 52.00M
March 31, 2022 51.00M
December 31, 2021 52.00M
September 30, 2021 47.00M
June 30, 2021 44.00M
March 31, 2021 39.00M
Date Value
December 31, 2020 40.00M
September 30, 2020 43.00M
June 30, 2020 46.00M
March 31, 2020 51.00M
December 31, 2019 53.00M
September 30, 2019 53.00M
June 30, 2019 58.00M
March 31, 2019 63.00M
December 31, 2018 67.00M
September 30, 2018 72.00M
June 30, 2018 79.00M
March 31, 2018 80.00M
December 31, 2017 89.00M
September 30, 2017 99.00M
June 30, 2017 105.00M
March 31, 2017 114.00M
December 31, 2016 120.00M
September 30, 2016 146.00M
June 30, 2016 153.00M
March 31, 2016 159.00M
December 31, 2015 148.00M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Supernus Pharmaceuticals, Inc. 124.20M
Eli Lilly & Co. 14.60B
Bristol Myers Squibb Co. 9.548B
Liquidia Corp. 54.95M
Harmony Biosciences Holdings, Inc. 220.87M